An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer genomics. Our NGS  technologies are among the most trusted in the world. Our sample-to-data solutions deliver high-quality, reproducible results to speed the discovery and analysis of cancer-related variants—and potentially transform the cancer care cycle. The use of Illumina benchtop instruments, such as MiSeq and NextSeq in conjunction with oncogenetic panels makes NGS affordable for any size lab.